🟢 Inovio Pharmaceuticals is trading 5% up with no identified company-specific catalyst

Inovio Pharmaceuticals is trading at $0.94, up 5.40%, with no new company-specific announcement identified to explain the October 28 move.

• The latest major company news remains the October 20 court judgment.
• XBI rose 2.18% during the regular session, offering sector context but not confirming the cause of Inovio’s move.
• Investors are approaching the FDA’s October 30 target decision for INO-3107, a near-term milestone, not a confirmed explanation for the rise.